Top in cardiology: Cannabis use, cholesterol guidance

The American Heart Association released a scientific statement that claims there is no documented benefit of cannabis use for CVD prevention or treatment. It was the top story in cardiology last week.

Another top story questions the suitability of the 2018 American College of Cardiology/American Heart Association Guideline on the Management of Blood Cholesterol, which researchers said does not flag younger patients with premature myocardial infarction (MI) as candidates for stain therapy before their event.

Read these and more top stories in cardiology below:

AHA: Evidence suggests no CV benefit, possible harm from cannabis use

There is no documented benefit of cannabis use for CVD prevention or treatment, according to a scientific statement from the American Heart Association. Read more.

Cholesterol guideline suitability questioned in younger patients with, at risk for MI

The 2018 American College of Cardiology/American Heart Association Guideline on the Management of Blood Cholesterol does not flag most younger patients with premature MI as candidates for stain therapy before their event, researchers found. Read more.

Younger women with PCOS at elevated risk for CVD

Women younger than 50 years with polycystic ovary syndrome were at elevated risk for CVD compared with younger women without it, according to a research letter published in the European Journal of Preventive Cardiology. Read more.

Disparities in cardiometabolic mortality worsened since 1999

Disparities in cardiometabolic mortality worsened between 1999 and 2017 between rural and urban Americans and within all race and sex groups for heart disease and diabetes, researchers found. Read more.

Acute MI fatality rate higher than expected during COVID-19 pandemic

In a cross-sectional study of patients with acute MI, there were more observed fatalities than expected during the early period of the COVID-19 pandemic. Read more.